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Mare Estrous Cycle
• 21 days
▫ 1 week estrus (i.e., “heat”)
 Follicular phase
 Follicle- Estrogen
▫ 2 weeks diestrus 
 Luteal phase
 Corpus Luteum (CL)- Progesterone
• Uterus
▫ Prostaglandin (PGF2α)
 Measured as PGFM
▫ Luteolysis
• Posterior Pituitary- Oxytocin
▫ Role in luteolysis Ovulation Ovulation
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Estrus Suppression in the 
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Methods of Estrus Suppression
• Administration of exogenous
progesterone/progestins
▫ E.g., Oral Altrenogest
• Extending the functional span of 
the corpus luteum (CL)
▫ Intrauterine glass ball
▫ Oxytocin
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• Released from the posterior pituitary gland
• Pulsatile nature
• Very short half-life 
• Functions
▫ Milk let-down
▫ Stimulates uterine contractions
▫ Oxytocin-Prostaglandin luteolytic pathway
• Therapeutic use to prolong CL function
▫ 8-Day Protocol (1x daily: days 7-14)
▫ Slow-release Oxytocin (SR-OT: two treatments)
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Hypothesis
• A two-injection proprietary SR-OT protocol will deliver an appropriate 
amount of oxytocin for a sufficient duration of time to inhibit luteolysis
Objectives
• Determine if IM administration of 2,400 IU of SR-OT once on days 7 and 
10 after ovulation would prolong CL function in treated mares 
compared to a non-treated control group
• Reduce number of injections from previous aqueous oxytocin methods
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Results
• 6/8 treated mares with prolonged luteal function*• 0/8 control mares with prolonged luteal function*
• Prolonged luteal function defined as >1 ng/ml for over 30 days
• * Prolonged function compared with Fisher’s exact test; P < .01 
Conclusions
• SR-OT administered on days 7 and 10 is an 
effective method of prolonging luteal function
• This proprietary SR-OT formulation provides a 
75% reduction in number of treatments needed 
in previous aqueous oxytocin methods
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Pro- vs Anti-Luteolytic Functions of Oxytocin
Pro-Luteolytic
• Oxytocin after day 10
▫ Binds to oxytocin receptor at 
endometrial epithelium
▫ Stimulates secondary messengers 
associated with PGF2α synthesis
 COX II
▫ PGF2α circulates through the blood 
stream and targets the CL
▫ CL undergoes luteolysis
Adapted from Neely, 1985
Pro- vs Anti-Luteolytic
Anti-Luteolytic
• Oxytocin administered before day 10 
and continued
▫ Binds to oxytocin receptor at 
endometrial epithelium
▫ Lack of secondary messenger
▫ Inhibits the upregulation of secondary 
messengers
 Specifically COX II
▫ No “spontaneous” luteolysis
▫ CL has prolonged function
 Up to 90 days
Adapted from Neely, 1985
